Over 85 firms are involved in providing fragment-based drug discovery-related services>>?>

According to experts in this field, fragment-based drug discovery solutions have facilitated the identification of viable pharmacological leads against otherwise hard to target biomolecules. In fact, many service provider companies are offering fragment libraries and support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus.
To order this 170+ page report, which features 55+ figures and 80+ tables, please visit this link 
The USD 1.6 billion (by 2030) financial opportunity within the fragment-based drug discovery market has been analyzed across the following segments:
Type of Screening Technique Used
X-ray Crystallography
Nuclear Magnetic Resonance
Surface Plasmon Resonance
Other Screening Techniques
  • Type of Service Offered
  • Library Screening
  • Fragment Screening
  • Fragment Optimization
End User
  • Industry Players
  • Non-Industry Players
Key geographical regions
North America (US and Canada)
Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)
The Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030 report features the following companies, which we identified to be key players in this domain:
  • 2bind
  • Charles River Laboratories
  • ChemAxon
  • ComInnex
  • Creative Biolabs
  • Creative Biostructure
  • Domainex
  • Evotec
  • Red Glead Discovery
  • SARomics Biostructures
  • Shanghai ChemPartner
  • Sygnature Discovery
  • Vernalis Research

Table of Contents

Press Release: Variation 3 (Format 4)
1. Preface

2. Executive Summary

3. Introduction

 4. Current Market Landscape

 5. Company Profiles: Fragment-based Drug Discovery Library and Service Providers 

 6. Partnerships and Collaborations

 7. Key Acquisition Targets

 8. Company Competitiveness Analysis

 9. Cost Saving Analysis

 10. Market Forecast and Opportunity Analysis

 11. Executive Insights
 12. Concluding Remarks
 13. Appendix 1: Tabulated Data
 14. Appendix 2: List of Companies and Organizations
 To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

Contact Details


Gaurav Chaudhary


+1 (415) 800 3415


You may also like


No comments yet... Be the first to leave a reply! Login here

0 Karma
1448 Posts

Made with by Mamby